The rising rates of invasive fungal infections caused by non-albicans Candida and the increasing emergence of antifungal resistance complicate the management of invasive candidiasis. Accurate and timely antifungal susceptibility testing is critical to targeting antifungal therapy. The purpose of this study was to compare commercially available susceptibility testing methods using prospectively collected Candida isolates. Susceptibility testing was performed on 74 Candida isolates collected from July 2014 to March 2015 using broth microdilution according to the Clinical and Laboratory Standards Institute method, Etest, Vitek 2 (YS-05) and Sensititre. Essential agreement and categorical agreement (CA) were assessed using the reference method. Of the 34 total blood isolates collected, Candida albicans comprised only 38 % (13) of the Candida spp. with Candida glabrata being nearly as prevalent (29 %, 10). CA using Etest was 86 % for fluconazole, 72 % for caspofungin, 98 % for micafungin and 97 % for anidulafungin. Vitek 2 CA was 90 % for fluconazole and 98 % for caspofungin. Sensititre CA was 93 % for fluconazole, 98 % for caspofungin, 98 % for micafungin and 100 % for anidulafungin. Although our study tested a small population of Candida isolates, our results were variable by method. When implementing antifungal susceptibility testing, clinicians should be aware of the strengths and limitations of each testing method.
INTRODUCTION
Candida spp. represent the fourth most common cause of healthcare-associated bloodstream infections, and invasive candidiasis (IC) contributes significantly to inpatient morbidity and mortality (Wisplinghoff et al., 2004; Magill et al., 2014) . Candida albicans has been the most commonly encountered species historically, but recent data reveal a growing prevalence of non-albicans Candida, notably Candida glabrata, Candida krusei, Candida parapsilosis and Candida tropicalis, as the cause of invasive infection (Tortorano et al., 2013; Bustamante et al., 2014; Pfaller et al., 2014) . Antifungal resistance remains rare in C. albicans, but there are a growing number of reports of nonsusceptibility in both albicans and non-albicans species (Alexander et al., 2013; Arendrup et al., 2013; Shields et al., 2013; Bustamante et al., 2014; Castanheira et al., 2014; Wang et al., 2015) . Both increased MIC and specific resistance mechanisms have been linked with treatment failure and mortality, making the choice of empiric therapy challenging for clinicians (Alexander et al., 2013; Shields et al., 2013; Wang et al., 2015) . Alterations of the echinocandin target enzyme, b-1,3-glucan synthase (encoded by FKS genes), is one such mutation linked to worsened clinical outcomes, and its prevalence appears to be increasing (Alexander et al., 2013; Beyda et al., 2014) . This changing epidemiology of candidiasis and increasing resistance have prompted the Infectious Disease Society of America to recommend broader empiric antifungal therapy in addition to organism identification and susceptibility testing (Pappas et al., 2016) . Health systems are faced with a difficult decision when choosing which product to utilize in their microbiology laboratories as cost, accessibility and feasibility vary among the commercially available testing platforms, and the optimal choice will be institution specific.
While broth microdilution (BMD) offers a valuable tool to identify fungal resistance, it remains inefficient for clinical use and has significant interlaboratory variability (CLSI, 2008 Espinel-Ingroff et al., 2013) . Commercially available susceptibility testing products have an important role in the care of patients with invasive fungal infections by providing clinicians with important patient-specific data to tailor therapy and facilitate 'step-down' therapy.
There are a variety of commercially available susceptibility testing methods, including BMD, disc diffusion and Sensititre YeastOne (Trek Diagnostic Systems; Thermo Scientific) BMD panels, E-testing and automated testing panels marketed by Vitek (bioM erieux) or Microscan (Beckman Coulter). Generally, these susceptibility testing methods have been compared individually to traditional BMD methods for approval and validation. Studies performing direct comparisons between multiple testing methods are limited. All systems accommodate fluconazole susceptibility assessment, but capacity to test echinocandin antifungals (anidulafungin, caspofungin and micafungin) remains limited. Some systems only assess caspofungin susceptibility. Interpretation of caspofungin MICs remains problematic, as there is significant evidence of interlaboratory variability and recommendations regarding breakpoints are conflicting (CLSI, 2012; Espinel-Ingroff et al., 2013; EUCAST, 2016) . While the caspofungin MIC has demonstrated correlation with the outcomes of patients treated with micafungin (Alexander et al., 2013; Shields et al., 2013; Beyda et al., 2014; Wang et al., 2015) , there have been reports of discordance between susceptibility of caspofungin and other echinocandins (Eschenauer et al., 2014) . The clinical significance of this discordance remains unknown.
Accurate and timely antifungal susceptibility testing is critical to the optimal management of IC. Commercially available susceptibility testing products vary greatly in both testing processes and diversity of antifungal agents evaluated. The purpose of this experiment was to compare susceptibility of clinical Candida isolates using commercially available susceptibility testing products.
METHODS
Isolates. Candida isolates identified through routine clinical laboratory analysis of inpatients utilizing Vitek 2 were prospectively collected from July 2014 to March 2015 under a protocol approved by the institutional review board. Any Candida isolate from a blood culture and any nonalbicans Candida isolated from any site were included. Duplicate isolates from the same patient were excluded. Once identified by routine hospital practice, isolates were subcultured onto fresh Sabouraud dextrose plates, and colonies were frozen in 25 % glycerol for storage at À80 C. C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) were utilized as quality control strains.
BMD. BMD was performed in duplicate according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 guidelines (CLSI, 2008) . Stock solutions of micafungin (Astellas Pharma US), caspofungin (Merck), anidulafungin (Pfizer) and fluconazole (Claris Lifesciences Limited) were created using commercially acquired drug powder diluted in sterile water. Categorical susceptibility was assessed using the CLSI M27-S4 breakpoints where applicable (CLSI, 2012) .
Vitek 2 (bioM erieux). The system was set up and maintained according to the manufacturer's recommendations, including up-todate quality control procedures. Isolates were analysed using the YS-05 yeast susceptibility card. MIC values were reported according to standard validation for clinical practice.
Etest (bioM erieux). Susceptibility testing was performed according to the manufacturer's directions using fluconazole, micafungin, anidulafungin and caspofungin testing strips plated over RPMI 1640 with 2 % glucose, 1.5 % Bacto agar and MOPS. Each measurement was assessed by the same two investigators with a third investigator designated to resolve discrepancies.
Sensititre custom frozen CLSI reference panel (Thermo Fisher Scientific). Study isolates that were analysed using custom frozen panels were obtained with gradient concentrations suitable for BMD of fluconazole, micafungin, caspofungin and anidulafungin according to the manufacturer's directions. Categorical susceptibility was assessed using the CLSI M27-S4 breakpoints where applicable (CLSI, 2012).
Study endpoints. The primary endpoint of this study was the categorical agreement (CA) of testing methods compared to reference BMD. CA was defined as the percentage of isolates classified in the same category (susceptible, intermediate or resistant) by the reference procedure and commercial system. CA was only assessed on isolates that have breakpoints in the most recently published CLSI guidance (Cuenca-Estrella et al., 2010) . MIC values at the lowest reported value for a testing method were considered comparable to any reading with a lower result using another method. Secondary endpoints included essential agreement (EA), defined as the absence of a discrepancy of more than two dilutions, percentage of isolates of varying species from blood cultures and the percentage of isolates identified as resistant to one or more antimycotic agents. Categorical discrepancies were considered very major errors (VMEs) 
RESULTS
Antifungal susceptibility testing was performed on a total of 74 isolates, including 34 isolated from blood culture bottles. The species distribution of study isolates is presented in Table 1 . Of the 34 bloodstream isolates, C. albicans was the most commonly isolated (38.2 %), followed by C. glabrata (29.4 %).
The CA and number of VMEs, MEs and MiEs varied among testing methods (Table 2) . Overall CA using Etest was 86 % for fluconazole, 72 % for caspofungin, 98 % for micafungin and 97 % for anidulafungin. For the Vitek 2 system, CA was 90 % for fluconazole and 98 % for caspofungin. CA using Sensititre was 93 % for fluconazole, 98 % for caspofungin, 98 % for micafungin and 100 % for anidulafungin. When evaluating the entire testing population of 74 isolates, including both the isolates from blood and additional nonalbicans isolates, EA using Etest was 87 % for fluconazole, 78 % for caspofungin, 97 % for micafungin and 93 % for anidulafungin. Vitek 2 EA was 92 % for fluconazole and 99 % for caspofungin. Sensititre EA was 93 % for fluconazole, 99 % for caspofungin, 99 % for micafungin and 96 % for anidulafungin.
The number of isolates with resistance to antifungals varied among testing methods (Table 3 , Fig. 1 ). The number of isolates with reduced susceptibility or resistance to fluconazole ranged from 4 to 11 depending on the testing method, while 17 isolates were classified as intermediate to caspofungin using Etest alone (no other method identified caspofungin resistance). Echinocandin resistance was rare overall (Table 4) . There were only 4 of the 34 (12 %) bloodstream isolates resistant to fluconazole using BMD.
There were five isolates (two C. albicans and three C. tropicalis) that had MIC values attained from BMD of !32 mg l À1 evidenced by undiminished growth in all study wells, despite having very low MIC values by both Etest and the Vitek 2 ( 2 mg l À1 ). A similar effect was observed in three C. albicans isolates using the frozen panels.
DISCUSSION
As antifungal usage becomes more widespread and resistance develops, antifungal susceptibility testing remains an area of rapid development with a high impact on clinical practice (Alexander et al., 2013; Arendrup et al., 2013; Shields et al., 2013; Bustamante et al., 2014; Castanheira et al., 2014; Wang et al., 2015; Pappas et al., 2016) . Accurate and timely susceptibility information ensures that patients will receive the most appropriate therapy with the highest chance for clinical success.
In this study, various Candida isolates were used to compare three commercially available susceptibility testing methods to the CLSI reference method (BMD). CuencaEstrella et al. (2010) compared the most common commercially available methods for fluconazole, amphotericin B, voriconazole and flucytosine, finding an average EA of >95 %. Their analysis included a wide range of Candida spp. but did not include analysis of the echinocandin antifungals. To our knowledge, our study is the first to evaluate the echinocandin antifungals that compare multiple susceptibility testing methods to BMD utilizing the new lower CLSI clinical breakpoints for these drugs (Cuenca-Estrella et al., 2010; CLSI, 2012).
In this study, the Vitek 2 system performed well, with EAs >90 % for fluconazole and caspofungin, which mirrors previously published information supporting the strong correlation between the Vitek 2 system and reference BMD (Posteraro et al., 2009; Peterson et al., 2011) . It is important to note that the range of reported MIC values of the Vitek 2 system is limited, making interpretation of intermediate isolates difficult. This is especially pertinent with caspofungin, as the lower limit of reporting ( 0.25 mg l À1 ) encompasses both susceptible and intermediate isolates of C. glabrata according to currently published CLSI breakpoints. It should be noted that this minimum value does equate to the EUCAST epidemiological cut-off value Antifungal agent Vitek 2 Etest Sensititre VME ME MiE VME ME MiE VME ME MiE In this study, the Etest method yielded the most errors and lowest agreement values for agents tested (Table 2) . While agreement for fluconazole was high, there was a trend towards increased MIC for C. glabrata. Caspofungin had the highest observed categorical disagreement, but agreement was much higher (>95 %) for the other echinocandins. Arendrup & Pfaller (2012) reported similar findings in a study of the Etest method with currently published CLSI breakpoints, demonstrating misclassification in 73.1 % of C. krusei and 33.1 % in C. glabrata (2012). Independent research has been conducted on alternative methods to interpret Etest strips, but these alternative methods are currently untested and poorly suited for routine use (Siopi et al., 2015) .
The overall high rate of agreement in this study with Sensititre (>90 %) is consistent with previous studies and surveys that have shown high degrees of correlation between BMD-based methods (Pfaller et al., 2002; Pfaller & Jones, 2006) . Institutions that wish to reliably evaluate echinocandins other than caspofungin must consider using a panel-based method. Unfortunately, studies using the CLSI or EUCAST method to assess caspofungin MIC have shown significant interlaboratory variability. Sensititre products appear to be the most reliable tool to complete this evaluation, and species-specific ECOFFs for resistance determination have been proposed that unfortunately vary significantly from CLSI breakpoints (Espinel-Ingroff et al., 2015) . Using the proposed Sensititre echinocandin ECOFFs, a number of isolates with reduced susceptibility were identified including five Candida lusitaniae [anidulafungin MIC 0.25, (4) micafungin MIC 0.25], one C. glabrata (micafungin MIC 0.06) and one C. albicans (micafungin MIC 0.12). As noted in the results, a number of C. tropicalis and C. albicans isolates varied in their susceptibility to fluconazole between the panel-based methods and Etest or Vitek 2. These scenarios accounted for all but one of the VMEs (13/14) identified for all testing methods across all isolates tested. Trailing growth, a noted limitation in the CLSI reference method and described previously, contributes to interlaboratory variability and may have led to this effect (Alexander et al., 2007; Alp et al., 2009; Pappas et al., 2016) . Generally, these isolates have been presumed to be clinically susceptible despite the elevated MIC value (CLSI, 2008 (CLSI, , 2012 . What role these discrepant results play in differences in therapeutic outcomes with echinocandins and fluconazole remains to be determined (Reboli et al., 2007; Andes et al., 2012; Pappas et al., 2016) .
Overall, a high rate of correlation was seen when comparing Etest, Vitek 2 and Sensititre to BMD using a small population of clinical Candida isolates. Low rates of agreement were observed for the caspofungin Etest among C. glabrata and C. krusei, suggesting that this method should be avoided in these species or alternative breakpoints should be used (Posteraro et al., 2009; Arendrup & Pfaller, 2012) . Despite CA, a trend towards increased fluconazole MIC was observed with the Etest method. Agreement was high using the Vitek 2, but antifungal evaluation remains limited in both ranges of MIC reported and agents tested. Sensititre panels offered the most accurate estimate of the reference method, although the process remains more time and resource intensive (Posteraro et al., 2015) . However, when implementing antifungal susceptibility testing methods, clinicians should be aware of the strengths and limitations of each testing method.
